



IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE PATENT OF: TAKAYA ET AL. :

PATENT NO. 4,935,507 :

ISSUED: JUNE 19, 1990 :

FOR: CRYSTALLINE 7-(2-(2-AMINOTHIAZOL-4YL)-2-HYDROXYIMINOACETAMIDO)-3-VINYL-3-CEPHEM-4-CARBOXYLIC ACID (SYN ISOMER) :

**Statement in Support of Petition for Correction of Inventorship of Patent No.
4,935,507 Under 37 C.F.R. § 1.324(B)(2)**

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

Sir:

I am Yasunobu Inaba. My current address is 11-6-807, Hakataekimae 4-chome, Hakata-ku, Fukuoka-shi, Fukuoka 812-0011 Japan. I am currently named as an inventor of the invention disclosed in U.S. Patent No. 4,935,507. I was named as an inventor in error, without any deceptive intent. I agree to the requested change of inventorship, in which Takao Takaya, Hitoshi Nakamura and I will be removed as inventors.

I declare that all statements made herein of my own knowledge are true and correct, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment or both, under 18 U.S.C. § 1001, and that such willful false statements may jeopardize the validity of the '507 patent.

Yasunobu Inaba

Yasunobu Inaba

July 12, 2006

Date



IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE PATENT OF: TAKAYA ET AL. :

PATENT NO. 4,935,507 :

ISSUED: JUNE 19, 1990 :

FOR: CRYSTALLINE 7-(2-(2-
AMINOTHIAZOL-4YL)-2-
HYDROXYIMINOACETAMIDO)-3-
VINYL-3-CEPHEM-4-CARBOXYLIC
ACID (SYN ISOMER) :

**Statement in Support of Petition for Correction of Inventorship of Patent No.
4,935,507 Under 37 C.F.R. § 1.324(B)(2)**

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

Sir:

I am Fumiyuki Shirai. My current address is 4-6-16, Jusohigashi, Yodogawa-ku,
Osaka-shi, Osaka 532-0023 Japan. I am a named co-inventor of the invention
disclosed in U.S. Patent No. 4,935,507. I agree to the requested change of inventorship,
in which Takao Takaya, Hitoshi Nakamura, and Yasunobu Inaba will be removed as
inventors, leaving me as the sole inventor.

I declare that all statements made herein of my own knowledge are true and
correct, and further that these statements were made with the knowledge that willful false
statements and the like so made are punishable by fine or imprisonment or both, under 18
U.S.C. § 1001, and that such willful false statements may jeopardize the validity of the
'507 patent.

Fumiyuki Shirai
Fumiyuki Shirai

2006/07/12
Date



IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE PATENT OF: TAKAYA ET AL. :

PATENT NO. 4,935,507 :

ISSUED: JUNE 19, 1990 :

FOR: CRYSTALLINE 7-(2-(2-
AMINOTHIAZOL-4YL)-2-
HYDROXYIMINOACETAMIDO)-3-
VINYL-3-CEPHEM-4-CARBOXYLIC
ACID (SYN ISOMER) :

**Statement of Astellas Pharma, Inc. in Support of Petition for Correction of
Inventorship of Patent No. 4,935,507 Under 37 C.F.R. § 1.324(B)(3)**

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

Sir:

Astellas Pharma, Inc., located at 3-11, Nihonbashe-Honcho 2-Chome, Chuo-Ku, Tokyo, Japan, is the sole assignee of U.S. Patent No. 4,935,507. This is evidenced by the properly-filed assignment, found at Reel 00534, Frame 0951, wherein Fujisawa Pharmaceutical Co., Ltd. was assigned the interests of Takao Takaya, Fumiyuki Shirai, Hitoshi Nakamura, and Yasunobu Inaba, the currently named inventors of the '507 patent. It is further evidenced by the properly-filed assignment, found at Reel 016500, Frame 0648, wherein Astellas Pharma, Inc. was assigned the interest of Fujisawa Pharmaceutical Co., Ltd.

Astellas Pharma, Inc. hereby agrees to the requested change of inventorship to remove Takao Takaya, Hitoshi Nakamura, and Yasunobu Inaba as inventors of U.S. Patent No. 4,935,507. Pursuant to 37 C.F.R. 3.73(b), I certify that I am an individual empowered to act on behalf of the assignee, Astellas Pharma, Inc., and that Astellas

Pharma, Inc. is the sole assignee of the above-captioned patent. I further certify that I have reviewed all the documents in the chain of title of the above-identified patent, including the above described assignments. Having reviewed these assignments, to the best of my knowledge and belief, all of the title in the above-identified patent is in Astellas Pharma, Inc.

Signature  Date July 24, 2006
Yuji Watanabe, Ph.D.
Director, Intellectual Property
ASTELLAS PHARMA INC.



THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE PATENT OF: TAKAO TAKAYA
ET AL.

PATENT NO. 4,935,507

ISSUED: JUNE 19, 1990

FOR: CRYSTALLINE 7-(2-(2-
AMINOTHIAZOL-4YL)-2-
HYDROXYIMINOACETAMIDO)-3-
VINYL-3-CEPHEM-4-CARBOXYLIC
ACID (SYN ISOMER)

Letter to Correct Inventorship

COMMISIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

Sir:

Attached is a Petition for Correction of Inventorship of U.S. Patent No. 4,935,507, to remove Takao Takaya, Hitoshi Nakamura, and Yasunobu Inaba as inventors. All of these were named as inventors through error. Such error arose without any deceptive intent on the part of any of these parties.

Along with the petition, please find:


- (1) Statements of Takao Takaya, Fumiyuki Shirai, Hitoshi Nakamura, and Yasunobu Inaba, the currently named inventors of U.S. Patent No. 4,935,507, pursuant to 37 C.F.R. § 1.324(b)(2).
- (2) Statement of Astellas Pharma Inc., assignee of U.S. Patent No. 4,935,507, pursuant to 37 C.F.R. § 1.324(b)(3); and

(5) Credit card payment in the amount of \$130.00 pursuant to 37 C.F.R. §
1.324(b)(4).

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.

Customer Number
22850



Richard D. Kelly
Attorney of Record
Registration No. 27,757

John D. Dellinger
Registration No. 50,436

Tel: (703) 413-3000
Fax: (703) 413 -2220
(OSMMN 08/03)



IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE PATENT OF: TAKAYA ET AL. :

PATENT NO. 4,935,507 :

ISSUED: JUNE 19, 1990 :

FOR: CRYSTALLINE 7-(2-(2-AMINOTHIAZOL-4YL)-2-HYDROXYIMINOACETAMIDO)-3-VINYL-3-CEPHEM-4-CARBOXYLIC ACID (SYN ISOMER) :

**Petition for Correction of Inventorship of Patent No. 4,935,507
Under 37 C.F.R. § 1.324**

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

Sir:

This is a petition to request that the Commissioner issue a certificate correcting the inventorship of U.S. Patent No. 4,935,507, to remove Takao Takaya, Hitoshi Nakamura, and Yasunobu Inaba as co-inventors. Takao Takaya, Hitoshi Nakamura, and Yasunobu Inaba were named as inventors earlier through error. Such error arose without any deceptive intent on the part of any party.

In support of this petition, and as required under 37 C.F.R. § 1.324, petitioner hereby submits the following:

(1) Statements of Takao Takaya, Hitoshi Nakamura, Fumiyuki Shirai, and Yasunobu Inaba, the currently named inventors of U.S. Patent No. 4,935,507, pursuant to 37 C.F.R. § 1.324(b)(2);

(2) Statement of Astellas Pharma Inc., assignee of U.S. Patent No. 4,935,507, pursuant to 37 C.F.R. § 1.324(b)(3); and

08/07/2006 JADD01 00000011 4935507

01 FC:1464


130.00 OP

(3) Credit card payment in the amount of \$130.00 pursuant to 37 C.F.R. §
1.324(b)(4).
Accordingly, having satisfied all the requirements for correction of inventorship,
petitioner requests a decision granting this petition to correct the inventorship of the '507
patent.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.

Customer Number
22850



Richard D. Kelly
Attorney of Record
Registration No. 27,757

John D. Dellinger
Registration No. 50,436

Tel: (703) 413-3000
Fax: (703) 413 -2220
(OSMMN 08/03)



IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE PATENT OF: TAKAYA ET AL. :

PATENT NO. 4,935,507 :

ISSUED: JUNE 19, 1990 :

FOR: CRYSTALLINE 7-(2-(2-AMINOTHIAZOL-4YL)-2-HYDROXYIMINOACETAMIDO)-3-VINYL-3-CEPHEM-4-CARBOXYLIC ACID (SYN ISOMER) :


**Statement in Support of Petition for Correction of Inventorship of Patent No.
4,935,507 Under 37 C.F.R. § 1.324(B)(2)**


COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

Sir:

I am Takao Takaya. My current address is 601-73, Sato, Awaji-shi, Hyogo 656-2143 Japan. I am currently named as an inventor of the invention disclosed in U.S. Patent No. 4,935,507. I was named as an inventor in error, without any deceptive intent. I agree to the requested change of inventorship, in which Hitoshi Nakamura, Yasunobu Inaba and I will be removed as inventors.

I declare that all statements made herein of my own knowledge are true and correct, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment or both, under 18 U.S.C. § 1001, and that such willful false statements may jeopardize the validity of the '507 patent.


Takao Takaya


Date



IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE PATENT OF: TAKAYA ET AL. :

PATENT NO. 4,935,507 :

ISSUED: JUNE 19, 1990 :

FOR: CRYSTALLINE 7-(2-(2-AMINOTHIAZOL-4YL)-2-HYDROXYIMINOACETAMIDO)-3-VINYL-3-CEPHEM-4-CARBOXYLIC ACID (SYN ISOMER) :

**Statement in Support of Petition for Correction of Inventorship of Patent No.
4,935,507 Under 37 C.F.R. § 1.324(B)(2)**

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

Sir:

I am Hitoshi Nakamura. My current address is 1-16 C-426, Aozein, Minoo-shi,
Osaka 562-0025 Japan. I am currently named as an inventor of the
invention disclosed in U.S. Patent No. 4,935,507. I was named as an inventor in error,
without any deceptive intent. I agree to the requested change of inventorship, in which
Takao Takaya, Yasunobu Inaba and I will be removed as inventors.

I declare that all statements made herein of my own knowledge are true and
correct, and further that these statements were made with the knowledge that willful false
statements and the like so made are punishable by fine or imprisonment or both, under 18
U.S.C. § 1001, and that such willful false statements may jeopardize the validity of the
'507 patent.


Hitoshi Nakamura
Hitoshi Nakamura

2006. 7. 12.
Date



Docket No.: 235956US40L

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313



ATTORNEYS AT LAW

RICHARD D. KELLY
(703) 412-6241
RKELLY@OBLON.COM

JOHN D. DELLINGER
(703) 413-3000
JDELLINGER@OBLON.COM

RE: U.S. Patent No.: 4,935,507
Applicants: Takao TAKAYA, et al.
Issue Date: June 19, 1990
For: CRYSTALLINE 7-(2-(2-AMINOTHIAZOL-4YL)-2-
HYDROXYIMINOACETAMIDO)-3-VINYL-3-CEPHEM-4-
CARBOXYLIC ACID (SYN ISOMER)

SIR:


Attached hereto for filing are the following papers:

Letter to Correct Inventorship; Petition for Correction of Inventorship of Patent No. 4,935,507 Under 37 CFR §1.324; Statements in Support of Petition for Correction of Inventorship of Patent No. 4,935,507 Under 37 CFR §1.324(b)(2); Statement of Astellas Pharma, Inc. in Support of Petition for Correction of Inventorship of Patent No. 4,935,507 Under 37 CFR §1.324(b)(3)

Our credit card payment form in the amount of \$130.00 is attached covering any required fees. In the event any variance exists between the amount enclosed and the Patent Office charges for filing the above-noted documents, including any fees required under 37 C.F.R. 1.136 for any necessary Extension of Time to make the filing of the attached documents timely, please charge or credit the difference to our Deposit Account No. 15-0030. Further, if these papers are not considered timely filed, then a petition is hereby made under 37 C.F.R. 1.136 for the necessary extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.


Richard D. Kelly
Attorney of Record
Registration No. 27,757

Customer Number

22850

(703) 413-3000 (phone)
(703) 413-2220 (fax)

John D. Dellinger
Registration No. 50,436